文献速递淋巴瘤

靶向MCL-1和BCL-2的 polatuzumab vedotin 联合维奈克拉克服复发/难治性非霍奇金淋巴瘤的治疗耐药:临床前模型与Ib期研究结果

Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
PubMed 文献 · Am J Hematol · 2023-01-17

在非霍奇金淋巴瘤细胞系和原发样本中,MCL-1被确定为维奈克拉的耐药因子;polatuzumab vedotin 通过泛素/蛋白酶体系统促进MCL-1降解。Ib期试验中,接受II期推荐剂量 polatuzumab vedotin 联合维奈克拉及抗CD20抗体的复发/难治性非霍奇金淋巴瘤患者,滤泡性淋巴瘤25/33(76%)和弥漫性大B细胞淋巴瘤5/17(29%)达到完全或部分缓解,安全性可接受。

要点

  • MCL-1是非霍奇金淋巴瘤中对维奈克拉耐药的因子。
  • polatuzumab vedotin 通过泛素/蛋白酶体系统促进MCL-1降解。
  • Ib期试验中滤泡性淋巴瘤缓解25/33(76%),弥漫性大B细胞淋巴瘤缓解5/17(29%)。

核心结论

  • 靶向MCL-1和BCL-2可克服复发/难治性非霍奇金淋巴瘤的治疗耐药,Ib期试验显示该联合方案在II期推荐剂量下具有可接受的疗效和安全性。

研究设计与样本

  • 临床前研究使用非霍奇金淋巴瘤细胞系和原发非霍奇金淋巴瘤样本。
  • Ib期临床试验(NCT02611323)纳入重度经治的复发/难治性非霍奇金淋巴瘤患者。

主要发现

  • 在非霍奇金淋巴瘤细胞系和原发样本中,MCL-1被确定为维奈克拉的耐药因子。
  • polatuzumab vedotin 通过泛素/蛋白酶体系统促进MCL-1降解。
  • 在临床前非霍奇金淋巴瘤模型中,MCL-1拮抗联合维奈克拉及抗CD20抗体(奥妥珠单抗或利妥昔单抗)导致肿瘤消退,且停药后消退持续。
  • Ib期试验中,接受II期推荐剂量 polatuzumab vedotin 联合维奈克拉及抗CD20抗体治疗的患者,滤泡性淋巴瘤25/33(76%)和弥漫性大B细胞淋巴瘤5/17(29%)达到完全或部分缓解,安全性可接受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of patients with relapsed or refractory lymphoid neoplasms represents a significant clinical challenge. Here, we identify the pro-survival BCL-2 protein family member MCL-1 as a resistance factor for the BCL-2 inhibitor venetoclax in non-Hodgkin lymphoma (NHL) cell lines and primary NHL samples. Mechanistically, we show that the antibody-drug conjugate polatuzumab vedotin promotes MCL-1 degradation via the ubiquitin/proteasome system. This targeted MCL-1 antagonism, when combined with venetoclax and the anti-CD20 antibodies obinutuzumab or rituximab, results in tumor regressions in preclinical NHL models, which are sustained even off-treatment. In a Phase Ib clinical trial (NCT02611323) of heavily pre-treated patients with relapsed or refractory NHL, 25/33 (76%) patients with follicular lymphoma and 5/17 (29%) patients with diffuse large B-cell lymphoma achieved complete or partial responses with an acceptable safety profile when treated with the recommended Phase II dose of polatuzumab vedotin in combination with venetoclax and an anti-CD20 antibody.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lasater EA, Amin DN, Bannerji R, et al. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. Am J Hematol. 2023. PMID: 36594167. doi:10.1002/ajh.26809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。